CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Other antidepressants (NaSSA)
Updated · Methodology
Mechanism
Domperidone has been associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death. This applies especially to people over 60, doses above 30 mg a day and use with QT-prolonging drugs or CYP3A4 inhibitors (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In a study in healthy volunteers, prolongation of the heart-rate-corrected QT interval (QTc) increased with mirtazapine concentration. At doses of 45 and 75 mg it stayed below the level considered clinically meaningful (mirtazapine SmPC, AEMPS, and label, US Food and Drug Administration, FDA). Post-marketing reports with mirtazapine describe QT prolongation, torsade de pointes, ventricular tachycardia and sudden death. Most occurred with overdose or in people with other risk factors, including concomitant QTc-prolonging drugs (mirtazapine SmPC, AEMPS, and label, FDA). According to both mirtazapine documents, the risk of QT prolongation and ventricular arrhythmias may increase with concomitant QTc-prolonging drugs (mirtazapine SmPC, AEMPS, and label, FDA). CYP3A4 handles most of domperidone metabolism (domperidone SmPC, AEMPS). The documents do not name mirtazapine as an inhibitor of this enzyme, and they give no data on either drug changing the levels of the other.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. QT prolongation and torsade de pointes ventricular tachycardia have been reported very rarely with domperidone (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With mirtazapine, QT prolongation, torsade de pointes, ventricular tachycardia and sudden death have been reported (mirtazapine SmPC, AEMPS, and label, US Food and Drug Administration, FDA). Low or high potassium, low magnesium and a slow heart rate raise the risk of arrhythmia (domperidone SmPC, AEMPS).
Management
The combination is contraindicated under the Spanish domperidone summary of product characteristics (SmPC). It contraindicates domperidone with QT-prolonging drugs and does not give a closed list (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Mirtazapine is not among the antidepressants given as examples. However, the warnings sections of the mirtazapine documents say that QTc prolongation increased with mirtazapine concentration. They also mention reports of QT prolongation and torsade de pointes with mirtazapine. Even so, in the volunteer study the effect stayed below the clinically meaningful level (mirtazapine SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The contraindication therefore covers mirtazapine too. The mirtazapine documents in turn ask for caution with other QTc-prolonging drugs and in people with cardiovascular disease or a family history of QT prolongation (mirtazapine SmPC, AEMPS, and label, FDA). Domperidone is also contraindicated in known QTc prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (domperidone SmPC, AEMPS). Use domperidone at the lowest effective dose, no more than 30 mg a day, usually for no longer than one week. If domperidone and mirtazapine have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS). No document gives an interval between stopping one drug and starting the other. The half-life of mirtazapine is 20–40 hours, occasionally up to 65 hours. The half-life of domperidone after a single oral dose is 7–9 hours in healthy people (mirtazapine and domperidone SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Remeron/RemeronSolTab (mirtazapine) prescribing information (2025)– FDA, DailyMed, Remeron/RemeronSolTab, Organon LLC, setid 98ad1917-a094-44f5-a28f-a64a8cfcd887, revisión 08/2025, secciones 4, 5.3, 5.8, 7 y 12.3
- AEMPS: Ficha técnica de Rexer Flas 15 mg comprimidos bucodispersables (mirtazapina) (2021)– AEMPS, CIMA, nº registro 64819, revisión 04/2021, secciones 4.3, 4.5 y 5.1
- AEMPS: Ficha técnica: Mirtazapina (nº registro 67068), sección 4.4 (2026)– AEMPS, CIMA, nº registro 67068, revisión 06/2026, sección 4.4
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5